XFOR MEXC RealStocks
Own real XFOR shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 07:27:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
X4 Pharmaceuticals, Inc. (XFOR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.98, with a market capitalization of $315.53M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.43 to $4.83. This page covers its latest market performance, valuation, price trends and company information.
$315.53M | |
$3.09 | |
$3.25 | |
$2.97 | |
$3.09 | |
522.26K | |
864.50K | |
-- | |
$4.83 | |
$2.43 | |
-- | |
2026-09-30 |
X4 Pharmaceuticals, Inc. (XFOR) last closed at $2.98 as of 2026-11-18 22:23:00, down 3.72% ($0.11) from the previous close of $3.09.
During the latest regular trading session, XFOR traded between $2.97 and $3.25, with a volume of 522.26K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, X4 Pharmaceuticals, Inc. (XFOR) moved from $3.25 to $2.98, representing a decline of 8.32% ($0.27).
The stock traded between $2.77 and $3.36 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 905.38 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 22.7%
XFOR is currently trading at $2.98, placing it 22.7% of the way from its 52-week low of $2.43 to its 52-week high of $4.83. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 45 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of X4 Pharmaceuticals, Inc. (XFOR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to XFOR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between XFOR shares and USD.
XFOR Shares to USD
1.00 XFOR shares = 2.975 USD
Calculations are estimates based on the latest available price and are for reference only.